Gao Q
Jiangsu Institute of Parasitic Diseases; WHO Collaborating Center for Research and Training on Malaria Elimination; Key Laboratory of National Health Commission on Parasitic Disease Control and Prevention; Jiangsu Provincial Key Laboratory on Parasite and Vector Control Technology, Wuxi 214064, China.
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2020 Apr 22;32(2):119-122. doi: 10.16250/j.32.1374.2020092.
A novel coronavirus disease (COVID-19) was identified in Wuhan City, Hubei Province of China by the end of 2019, and then, the disease spread across China and became a global pandemic. Nevertheless, there are no effective treatments or vaccines for COVID-19 until now. In addition to the treatment of patients with COVID-19, the China Medical Treatment Expert Group for COVID-19 is active to study and screen effective antiviral drugs, and has found that chloroquine, an old antimalarial,shows activity against SARS-CoV-2. Then, chloroquine was included in the Guidelines for the Diagnosis and Treatment of COVID-19 in China (version 6) issued by National Health Commission of the People's Republic of China. Currently, chloroquine phosphate and hydroxychloroquine sulfate, two chloroquine derivatives, are under clinical use. Although these two agents exhibit similar mechanisms of drug actions, there is a difference between these two chemicals in terms of target populations, therapeutic efficacy and adverse reactions. This paper summarizes the currently available data and experiences from clinical treatment for malaria with chloroquine drugs, so as to provide insights into the more rational use of chloroquine agents for the treatment of COVID-19.
2019年底，中国湖北省武汉市发现了一种新型冠状病毒病（COVID-19），随后，该病在中国蔓延并成为全球大流行疾病。然而，截至目前，尚无针对COVID-19的有效治疗方法或疫苗。除了对COVID-19患者进行治疗外，中国COVID-19医疗救治专家组积极开展有效抗病毒药物的研究和筛选，并发现一种古老的抗疟药氯喹对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）具有活性。随后，氯喹被纳入中华人民共和国国家卫生健康委员会发布的《新型冠状病毒肺炎诊疗方案（试行第六版）》。目前，磷酸氯喹和硫酸羟氯喹这两种氯喹衍生物正在临床使用。尽管这两种药物表现出相似的药物作用机制，但这两种化学物质在目标人群、治疗效果和不良反应方面存在差异。本文总结了目前使用氯喹类药物治疗疟疾的临床治疗数据和经验，以便为更合理地使用氯喹类药物治疗COVID-19提供见解。
